SCHEMBL2840566

SCHEMBL2840566

O=[N+]([O-])c1ccc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
CSF1R P07333 8/20 0.42
PTPN1 P18031 1/20 0.40
RIPK1 Q13546 2/20 0.40
RIPK3 Q9Y572 1/20 0.40
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT3 P36888 1/20 0.40
KDM1A O60341 1/20 0.39
ITK Q08881 1/20 0.38
PIK3CD O00329 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
CSNK1D P48730 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3637760 0.91 RIPK1 (0.42) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL14024731 0.84 CSF1R (0.48) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL13322413 0.83 USP30 (0.44) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2848854 0.81 RAB9A (0.43) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2848851 0.81 RAB9A (0.43) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2840488 0.81 CSF1R (0.56) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2677488 0.80 CSF1R (0.55) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2677134 0.79 CSF1R (0.48) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2676754 0.79 CSF1R (0.48) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL4550946 0.79 CSF1R (0.58) NPC1RAB9AMAPTPKMCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 NPC1 2714/4885RAB9A 1826/4885MAPT 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.